Detalhe da pesquisa
1.
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.
Allergy
; 77(3): 897-906, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34460948
2.
Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes.
Br J Dermatol
; 187(4): 539-547, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35656793
3.
Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement.
J Am Acad Dermatol
; 86(3): 551-562, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34044102
4.
An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata.
Allergy
; 76(10): 3053-3065, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33721346
5.
Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation.
J Am Acad Dermatol
; 84(2): 370-380, 2021 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-32376430
6.
Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial.
J Am Acad Dermatol
; 82(2): 360-365, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-31279028
7.
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab.
J Allergy Clin Immunol
; 143(1): 142-154, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30121291
8.
The impact of dupilumab treatment on SARS-CoV-2 T cell responses in atopic dermatitis patients.
Allergy
; 78(2): 571-574, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36181718
9.
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.
J Am Acad Dermatol
; 78(5): 872-881.e6, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29353025
10.
The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis.
Ann Allergy Asthma Immunol
; 128(6): 734-736, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35346880
11.
Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis.
J Allergy Clin Immunol
; 147(1): 394-397, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32428528
12.
Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot study.
J Am Acad Dermatol
; 85(6): 1657-1660, 2021 12.
Artigo
Inglês
| MEDLINE | ID: mdl-33440217
13.
Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis.
Cutis
; 95(1): 47-51, 2015 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-25671445
14.
Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.
J Am Acad Dermatol
; 81(3): 857-859, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31078609
15.
Magnesium supplementation in the treatment of pseudoxanthoma elasticum: A randomized trial.
J Am Acad Dermatol
; 81(1): 263-265, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-30826287
16.
A single-blinded randomized controlled study to assess the efficacy of twice daily application of sinecatechins 15% ointment when used sequentially with cryotherapy in the treatment of external genital warts.
J Drugs Dermatol
; 13(11): 1400-5, 2014 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-25607709
17.
An integrated model of alopecia areata biomarkers highlights both TH1 and TH2 upregulation.
J Allergy Clin Immunol
; 142(5): 1631-1634.e13, 2018 11.
Artigo
Inglês
| MEDLINE | ID: mdl-29981808
18.
Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV-VI.
Arch Dermatol Res
; 315(2): 215-221, 2023 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-35279741
19.
Secukinumab responses vary across the spectrum of congenital ichthyosis in adults.
Arch Dermatol Res
; 315(2): 305-315, 2023 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-35218370
20.
A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.
Arch Dermatol Res
; 315(2): 181-189, 2023 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-35230488